Compare Moderna, Inc. (MRNA) vs Westinghouse Air Brake Technologies Corporation Common Stock (WAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? Moderna, Inc. trades at $225.06 (market cap $86.33B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $285.55 (market cap $48.39B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| MRNA | WAB | |
|---|---|---|
Market Cap | $86.33B | $48.39B |
Volume | 13,361,426 | 960,464 |
Sector | Health | Industrials |
52-Week High | $226.30 | $305.79 |
52-Week Low | $22.36 | $193.43 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $54.30B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Westinghouse Air Brake Technologies Corporation Common Stock
Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →
